Attached files

file filename
EX-31.2 - EX-31.2 - Kite Pharma, Inc.kite-ex312_7.htm
EX-31.1 - EX-31.1 - Kite Pharma, Inc.kite-ex311_6.htm
EX-32.1 - EX-32.1 - Kite Pharma, Inc.kite-ex321_10.htm
EX-10.2 - EX-10.2 - Kite Pharma, Inc.kite-ex102_193.htm
EX-10.3 - EX-10.3 - Kite Pharma, Inc.kite-ex103_166.htm
EX-10.1 - EX-10.1 - Kite Pharma, Inc.kite-ex101_196.htm
XML - IDEA: XBRL DOCUMENT - Kite Pharma, Inc.R9999.htm
10-Q - 10-Q - Kite Pharma, Inc.kite-10q_20150630.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Kite Pharma, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Cynthia M. Butitta, Chief Operating Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

By:

 

/s/ Cynthia M. Butitta

 

 

Name:   Cynthia M. Butitta

 

 

Title:     Chief Financial Officer and Chief Operating Officer

 

Date:             August 10, 2015

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.